---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106545"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:35:36.598856+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M

## Summary
- Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
- Selected 90 mg once-daily palazestrant for OPERA-01 Part 2 and OPERA-02 frontline combo trial with ribociclib.
- OPERA-01 top-line data expected H2 2026; OPERA-02 initiation on track for Q3 2025.
- Cash, equivalents, and marketable securities $361.9M as of June 30, 2025.
- Mature palazestrant+ribociclib Phase 1b/2 data to be presented at ESMO 2025; OP-3136 Phase 1 enrolling.

## SEC filing metadata
- accession: 0000950170-25-106545
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/0000950170-25-106545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106545
- JSON: https://secwatch.observer/filing/0000950170-25-106545.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.